Immunotherapy in HCC: aetiology matters

eGastroenterology 2026 Open access

Read full text
Authors: Irene Oi‐Lin Ng, Guoyue Lyu
DOI: 10.1136/egastro-2026-100465
Cited by: 1
References: 7

Abstract

The therapeutic landscape of advanced hepatocellular carcinoma (HCC) has undergone a paradigm shift with the advent of immune checkpoint blockade (ICB).

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment

Publication details

Journal / source
eGastroenterology
Publisher
BMJ
Volume
4
Issue
2
Pages
e100465–e100465
Publication date
1 April 2026
Language
EN